Krystal Biotech — Vyjuvek (beremagene geperpavec) $KRYS
for dystrophic epidermolysis bullosa
MHRA approved beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa.
for dystrophic epidermolysis bullosa
MHRA approved beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa.
Dystrophic epidermolysis bullosa is an inherited disease that causes extremely fragile skin and painful blisters from minor friction or trauma. Vyjuvek is a topical gene therapy that delivers a working copy of the collagen-producing gene directly to skin wounds. By helping skin cells produce the essential collagen they lack, this treatment may promote durable wound healing and reduce the burden of recurrent blisters.
To determine whether administration of topical B-VEC improves wound healing as compared to placebo, and to evaluate durability, repeat dosing (Primary Endpoint) and further obtain safety and tolerability data.
Source: ClinicalTrials.gov